Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel N-(Heterocyclylphenyl)benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the β-Catenin Armadillo Repeats Domain as an Anticancer Agent

3 Jul 2023

Abstract excerpt

High Resolution Image Download MS PowerPoint Slide Despite intensive efforts, no inhibitors of the Wnt/β-catenin signaling pathway have been approved so far for the clinical treatment of cancer. We synthesized novel N -(heterocyclylphenyl)benzenesulfonamides as β-catenin inhibitors. Compounds 5 – 10 showed strong inhibition of the luciferase activity. Compounds 5 and 6 inhibited the MDA-MB-231, HCC1806, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to HER2/EGFR in Cancer Research
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37470018
DOI: 10.1021/acsptsci.3c00092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel N-(Heterocyclylphenyl)benzensulfonamide Sharing an Unreported Binding Site with T-Cell Factor 4 at the β-Catenin Armadillo Repeats Domain as an Anticancer AgentPMID 37470018Read ↗

Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeuticsSemantic proximity Read ↗

Condensate screening identifies YM155 as β-catenin condensate inhibitor in colorectal cancerSemantic proximity Read ↗

β-catenin inhibitors in cancer therapeutics: intricacies and way forwardSemantic proximity Read ↗

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.Semantic proximity Read ↗

Targeting BACH1 by HPPE inhibits the Wnt/β-catenin pathway and malignant phenotype in glioblastoma cells.Semantic proximity Read ↗

Discovery of small molecule inhibitors of the PTK7/β-catenin inter-action targeting the Wnt signaling pathway in colorectal cancerSemantic proximity Read ↗

Discovery of Small-Molecule Inhibitors of the PTK7/β-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer.Semantic proximity Read ↗

Targeting Wnt/β-Catenin Pathway for Drug TherapySemantic proximity Read ↗

Tcf4 can specifically recognize beta-catenin using alternative conformations.Semantic proximity Read ↗

Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

Wnt breakers in colon cancer.Semantic proximity Read ↗

Design and Synthesis of Novel Diaminoquinazolines with <i>in Vivo</i> Efficacy for β-Catenin/T-Cell Transcriptional Factor 4 Pathway InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.